Oxford scientists are preparing to rapidly produce new versions of their vaccine to combat emerging more contagious Covid-19 variants discovered in the UK, South Africa and Brazil, The Telegraph reported.

Human trials of a coronavirus vaccine combining Russia’s Sputnik V shot with that developed by Britain’s AstraZeneca and Oxford University are expected to start in early February, the chairman of Russian drugmaker R-Pharm told Reuters.

Mesenchymal stem cells derived from umbilical cord tissue could help treat ARDS in Covid-19 patients, according to results of a Phase I/IIa clinical trial published by University of Miami researchers.

Seattle-based AltPep Corporation raised $23.15 million in a Series A financing round to take the company’s breakthrough amyloid targeting platform to development.

When it comes to matters of heart health, no amount of exercise is too much, scientists said regarding research that debunks the myth that high levels of vigorous physical activity might not always be beneficial.

A roundup of scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes research on Covid-19 patients who still have symptoms 6 months after falling ill.

Evidence continues to build for long-lasting immunity to Covid-19 following disease infection, with the publication of a new study showing a durable immune response as far as eight months after the initial onset of symptoms.

Britain became the first country to vaccinate its population with Oxford University and AstraZeneca’s Covid-19 shot on Jan. 4, but Prime Minister Boris Johnson was set to tighten restrictions in England in a bid to slow the spread of cases.

Experts at India’s drugs regulator recommended two coronavirus vaccines for emergency use: one developed by AstraZeneca and Oxford University, and the other backed by a state-run institute.

The Covid-19 vaccine developed by British drugmaker AstraZeneca Plc and Oxford University will likely be authorized for emergency use in the United States in April 2021, the chief adviser for the U.S. Covid-19 vaccine program said.